Evotec (NASDAQ:EVO) Shares Fall to $4.70

Shares of Evotec SE ( NASDAQ:EVO – Get Free Report ) fell before the market opened on Thursday. The stock had previously closed at $4.70 but opened at $4.60. Evotec shares last traded at $4.54 on volume of 10,295 shares.

Changes in analyst ratings

Several analysts have recently issued reports on shares of EVO. Deutsche Bank Aktiengesellschaft raised shares of Evotec from a “hold” rating to a “buy” rating in a research report on Friday, April 12. HC Wainwright reissued a “buy” rating and set an $11.00 price target on shares of Evotec in a research report on Thursday, May 23.

Check out our latest report on Evotec

Evotec price performance

The stock has a fifty-day simple moving average of $5.02 and a two-hundred-day simple moving average of $7.20. The company has a debt to equity ratio of 0.43, a current ratio of 1.86 and a quick ratio of 1.79.

Hedge funds bet on Evotec

Institutional investors and hedge funds have been buying and selling shares of the company recently. Quadrant Capital Group LLC acquired a new position in Evotec during the fourth quarter valued at approximately $25,000. Cetera Advisors LLC acquired a new position in Evotec during the first quarter worth approximately $188,000. Optiver Holding BV increased its stake in Evotec by 643.1% during the 4th quarter. Optiver Holding BV now owns 80,810 shares of the company’s stock valued at $945,000 after acquiring an additional 69,936 shares during the period. Finally, Mubadala Investment Co PJSC acquired a new position in Evotec during the fourth quarter worth approximately $53,931,000. Hedge funds and other institutional investors hold 5.81% of the company’s shares.

About Evotec

(Download the free report)

Evotec SE operates as a drug discovery and development partner for the pharmaceutical and biotechnology industries worldwide. The company develops pharmaceutical products in various therapeutic areas such as autoimmune diseases, cancer, central nervous system diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis and women’s health.

See also

Get news and ratings for Evotec Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Evotec and related companies in MarketBeat.com’s FREE daily email newsletter.